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Abstract
Background: Chromosomal fragile sites are heritable specific loci especially prone to breakage. Some of them are associated
with human genetic disorders and several studies have demonstrated their importance in genome instability in cancer.
MicroRNAs (miRNAs) are small non-coding RNAs responsible of post-transcriptional gene regulation and their involvement
in several diseases such as cancer has been widely demonstrated. The altered expression of miRNAs is sometimes due to
chromosomal rearrangements and epigenetic events, thus it is essential to study miRNAs in the context of their genomic
locations, in order to find significant correlations between their aberrant expression and the phenotype.
Principal Findings: Here we use statistical models to study the incidence of human miRNA genes on fragile sites and their
association with cancer-specific translocation breakpoints, repetitive elements, and CpG islands. Our results show that, on
average, fragile sites are denser in miRNAs and also in protein coding genes. However, the distribution of miRNAs and
protein coding genes in fragile versus non-fragile sites depends on chromosome. We find also a positive correlation
between fragility and repeats, and between miRNAs and CpG islands.
Conclusion: Our results show that the relationship between site fragility and miRNA density is far more complex than
previously thought. For example, we find that protein coding genes seem to be following similar patterns as miRNAs, if
considered their overall distribution. However, once we allow for differences at the chromosome level in our statistical
analysis, we find that distribution of miRNA and protein coding genes in fragile sites is very different from that of miRNA.
This is a novel result that we believe may help discover new potential correlations between the localization of miRNAs and
their crucial role in biological processes and in the development of diseases.
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Introduction
Chromosomal fragile sites are heritable specific loci especially
prone to breakage and rearrangements when cells are exposed to
specific culture conditions or certain chemical agents such as
inhibitors of DNA replication or repair [1,2,3]. They can be
classified as rare or common, according to their frequency within
the population. Rare fragile sites are present in a small fraction of
the population and are usually associated with human genetic
disorders, while common fragile sites are present in all individuals
and, thus, represent a component of normal chromosome
structure. A number of fragile sites span genes encoded by very
large genomic regions. The observed rearrangements, affecting the
associated genes, are usually insertions, deletions or translocations.
Moreover, it has been shown that many genes involved in cancer-
specific recurrent translocations are located within fragile sites [4].
This often results in the expression of altered oncogenes or the loss
of tumor suppressors, contributing to the initiation of cancer [5,6].
MicroRNAs [miRNAs] are endogenous small non coding RNAs
responsible of post-transcriptional gene regulation [7]. They
regulate specific target genes expression through the association
with a large, multi-protein complex called RNA Induced Silencing
Complex [RISC]. miRNAs into RISC recognize their targets by
the binding of their bases to partially complementary sites usually
located in the 39 UTR region of their targets. However, functional
miRNA binding sites can also occur within the 59 UTR [8] or
coding region [9]. miRNAs have been reported to be involved in
many biological processes, including developmental timing,
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[10,11,12]. Their oncogenicity has been demonstrated in a variety
of cancers and their aberrant expression due to chromosomal
rearrangements has been reported [13,14]. For example, miR-15
and miR-16 are located at chromosome 13q14, a region deleted in
B cell chronic lymphocytic leukemia [CLL], and it has been shown
that both miRNAs are deleted or down-regulated in the majority
of CLL cases [14,15]. miRNA expression can also be regulated by
epigenetic mechanisms [16]. Some miRNAs are down-regulated
while others are over-expressed, and they can act as tumor-
suppressor genes or oncogenes, respectively. Tumor-suppressor
genes can be aberrantly methylated in cancer, and consequently
down-regulated. The tumor-suppressor gene WWOX, located
within the fragile site FRA16D, is correlated to multiple cancers,
especially breast, prostate and ovary [17,18]. A vastly studied
mechanism of reducing WWOX at the transcriptional level is the
hyper-methylation of CpG islands in its promoter and coding
region [18]. Fragile sites are often characterized by repetitive
sequences. Folate sensitive rare fragile sites have been found to
represent loci with expansive mutations of the normally occurring
CCG/CGG trinucleotide repeat sequences adjacent to a CpG
island [19,20], while non-folate sensitive rare fragile sites have
been found to comprise polymorphic AT-rich minisatellite repeats
[21,22]. Fragile sites may also consist of other repetitive elements.
For example, the nucleotide sequence of FRA6F is rich in
repetitive elements like LINE1 and LINE2, Alu, MIR, MER and
endogenous retroviral sequences and shows several DNA segments
with increased helix flexibility [23]. Alu elements are the most
abundant class of interspersed repeat sequences [24]. Recently, it
was reported that some mammalian miRNAs are derived from
genomic repeats and some of them show perfect complementarity
with the MIR/LINE-2 class of repeat elements, which are present
within a large number of human mRNAs and EST transcripts that
contain portions of MIR and other LINE-2 elements in their 39-
untranslated regions [25]. It has been hypothesized that Alu
elements within 39-UTRs are targeted specifically by certain
miRNAs [26]. Previous works showed that miRNA genes are
frequently located at fragile sites and cancer-related genomic
regions [6,27,28]. Here we present the complete mapping of the
human miRNA genes on fragile sites, cancer-specific translocation
breakpoints, repetitive sequences and CpG islands. The aim of this
work is to highlight the potential connections between the
localization of miRNAs and their role in biological processes
and in the development of diseases.
Results
Overall fragile sites are particularly dense in miRNAs and
protein coding genes
The mapping of human miRNA genes revealed that 242 of 715
miRNAs (33.8%) are located in chromosome fragile sites,
sometimes overlapping with genes mapped on translocation
breakpoints (see Table S1). This is a notable finding, considering
that fragile sites account for about 25.8% of the length of all sites
considered together and seems to indicate a higher than expected
concentration of miRNA in fragile sites (see Table 1). In order to
understand if this is a peculiarity of miRNAs we also mapped
protein coding genes on fragile sites and obtained a similar
percentage (7,446 of 21,945 genes, i.e. 33.9%, are located in
fragile sites). Hence, it appears that the overall distribution of
genetic material tends to be denser in fragile sites and that this is
not only a characteristic of miRNA, unlike previous literature
seemed to suggest. In addition, the analysis performed using a
zero-inflated Poisson regression for the miRNAs and a Poisson
regression model for the genes, reveals also that fragile sites
contain more miRNAs and more genes than non-fragile regions
(Fragile IRRgenes=1.346; Fragile IRRmiRNAs=1.523, conditioned
on a non-zero value being observed; Fragile IRRmiRNAs=1.354,
unconditional, i.e., whether we observe a zero or a non-zero
value). In this analysis, chromosome-specific effects are accounted
for and the differing lengths of each region are considered as
exposure controls (see Table 2). Though the results seem to
indicate the tendency for a higher incidence of miRNAs in fragile
sites when compared to genes (conditional and unconditional
Fragile IRRmiRNAs . Fragile IRRgenes), the difference is not
statistically significant (p.0.05).
Moreover, 317 of 715 miRNAs (44.3%) are located within genes
which are translocated in cancer and 87 of them (27.4%) are also
in fragile sites. When looking in detail chromosome by
chromosome, we find that chromosome 19 has the highest
number of miRNAs and genes in fragile regions, while no
miRNAs have been yet found in the fragile sites of chromosome 20
(Table S2). This result seems to suggest that incidence of genetic
material might depend on the specific chromosome considered.
The incidence of miRNAs on fragile versus non-fragile
sites depends on chromosome
Though the previous analysis seems to demonstrate that there
are little overall differences between miRNAs and protein coding
genes with respect to their incidence across fragile versus non-
fragile regions, further analysis reveals significant differences across
chromosomes (see Table S3). miRNAs show a greater incidence in
Table 1. Overall Descriptive Statistics.
Fragile
Regions
Non-Fragile
Regions Total
Number of regions 105 100 205
Average length (mbp) 7.45 22.42 14.76
miRNA
Total number 242 473 715
Average per region 2.30 4.73 3.49
Average per unit of length 0.31 0.21 0.24
Protein coding genes
Total number 7,446 14,499 21,945
Average per region 70.91 144.99 107.05
Average per unit of length 9.52 6.47 7.25
doi:10.1371/journal.pone.0011166.t001
Table 2. Model Results — Fragile Incidence Rate Ratios (IRR).
miRNA Model
(conditional)
miRNA Model
(unconditional)
Protein Coding
Genes Model
Fragile IRR Estimate 1.523 1.366 1.347
95% Confidence
Interval
[1.256, 1.845] [1.151, 1.621] [1.306, 1.388]
*Conditional IRR considers the impact of fragility given that the miRNA value in
a region is greater than 0; unconditional IRR considers the impact of fragility
overall, even when including zero-valued regions;
(ZIP model for miRNA and standard Poisson model for genes; model controls
for differential exposure due to length and chromosome heterogeneity).
doi:10.1371/journal.pone.0011166.t002
miRNAs in Fragile Sites
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Fragile IRRmiRNA_c19=29.391, an extremely high value). How-
ever, within chromosome 14 we observe the opposite result: in this
chromosome there is a lower incidence of miRNAs in fragile
regions (Fragile IRRmiRNA_c14=0.244). For all other chromo-
somes, fragile regions have neither a greater nor a lower incidence
of miRNA. This means that the overall average result we reported
previously was being driven by regions in few chromosomes
(chromosomes 16, 19, and X). Indeed, once we allow for fragility
to predict miRNA incidence differently in each chromosome
(allow for the interaction of fragility dummy and chromosome) the
overall effect of fragile (across all chromosomes) becomes
insignificant (p.0.05). For genes we observe a more complex
result. Chromosomes 2, 7, 8, 11, 12, 16, 19, 20, 22, and X show a
greater incidence of genes in fragile regions. In contrast,
chromosomes 5, 9, 13, and 17 show a lower incidence of genes
in fragile regions. All other chromosomes do not show any
significant incidence difference in fragile sites versus non-fragile
regions (see Table S3). Note also that the extreme values we found
in the incidence of miRNA were not detected for genes (the
maximum Fragile IRR is IRRgenes_c19=8.899). This is an
important finding. Though chromosome 19 seems denser in
fragile regions (higher incidence of both miRNAs and genes than
remaining chromosomes), the incidence of miRNAs is 29 times
higher versus 9 times higher for genes.
Hence, we conclude that the incidence of miRNAs in fragile
sites is significantly different from that of protein coding genes
when looking at specific chromosomes, though the overall
incidence across all chromosomes seemed (after the first analysis)
to be the similar.
Sites with more repeats are slightly more likely to be
fragile
The results of the Logit model analysis on site fragility, using
repeats per unit of length and CpG islands per unit of length as
predictors, show that fragile sites are positively correlated to
repeats (coefficient_repeat_mpg=0.002 with p=0.026) but not to
CpG islands (p.0.05). Conversely, when modeling repeats as a
function of site fragility, chromosome dummies, miRNAs and gene
count, we find that repeats are significantly and positively
correlated to miRNAs and to the number of genes and that, on
average, repeats are 10% more frequent on fragile sites.
Interestingly, when we performed the same kind of analysis on
CpGs, we found that on average CpGs are 32% more frequent on
fragile sites though CpGs were not significant in the fragile Logit
model (i.e., CpGs were not predictive of fragility but fragile sites
tend to have a greater incidence of CpGs). CpGs are also positively
correlated to miRNA and protein coding genes.
Sites with more repeats are less likely to contain miRNA
and genes; sites with more CpG islands are more likely to
contain miRNA and genes
We re-estimated the miRNA and genes models introducing the
repeats and CpG variables (in thousands, for better scaling). We
find that miRNA and genes are less frequent with more repeats
(Repeats IRRmiRNA=0.985 and Repeats IRRgenes=0.988, with
p,0.05 for both) and that miRNA and genes are more frequent
when there is a greater incidence of CpGs (CpG IRR-
miRNA=1.165 and CpG IRRgenes=1.213, with p,0.05 for both).
In addition, repeats and CpG results for miRNA and Genes do not
present significant differences (the 95% confidence intervals in
both models overlap and the test for their difference has
p=0.267). Table 3 summarizes these results.
After accounting for the effects of Repeats and CpG
islands we find that miRNA and Gene baseline incidence
still varies significantly across chromosomes and the
effect of site fragility (specific to each chromosome) is
also still present
Even after accounting for the effects of Repeats and CpG
islands on miRNA and gene incidence we observe that effects of
site fragility specific to each chromosome are still statistically
significant; and though some of the effects change slightly (e.g.,
updated Fragile IRRmiRNA_c19=15.867 and updated Fragile
IRRgenes_c19=3.458) the overall results (direction and relative
magnitude) hold (see Table S4). This means that the effect of site
fragility seems not to be due solely to the stronger presence of
repeats and CpG islands in those regions. There are other factors
associated with site fragility beyond repeats and CpGs that are
relevant for miRNA and gene incidence (because of the extremely
high correlation between Repeats and CpGs at some of the
chromosomes, we are unable to also include effects of repeats
CpGs specific to each chromosome). Finally, also the baseline
incidence of miRNA and genes in each chromosome vary
significantly even after accounting for the effects of repeat and
CpGs. This baseline incidence can be seen in Table S5 and should
be further studied and linked to specific diseases (e.g., in
chromosome X miRNAs are 3 times more frequent than average
and protein coding genes are 23% less frequent than average).
Discussion
Previous studies [6,27] compared the genome positions of fragile
sites and cancer susceptibility loci, with those of miRNAs in human
and mouse. Results suggested a statistically significant association
between the chromosomal locations of miRNAs and those of fragile
sites and of regions involved in cancer. In our study we extended
Calin’swork[6] toallcurrentlyknownhumanmiRNAs(todaythere
are more than 700 known miRNA, and at the time of Calin’s work
only about 200 were known). In addition, we also considered the
location of protein coding genes and studied whether these followed
similar patterns as miRNAs, an analysis that previous work had not
considered. The results of our analysis show that fragile sites are
particularly dense in miRNAs (confirming Calin’s findings) and also
in protein coding genes. Our overall initial results also indicated no
significant difference between miRNAs and genes in terms of their
distribution in fragile versus non-fragile sites.
Table 3. Repeat and CpG IRR Results for miRNA and Genes.
Variable miRNA Protein Coding Genes
IRR*
95% Confidence
Interval IRR
95% Confidence
Interval
Repeats
(in thousands)
0.985 [0.979, 0.992] 0.988 [0.978, 0.990]
CpG Islands
(in thousands)
1.165 [1.067, 1.272] 1.213 [1.194, 1.232]
*Conditional and unconditional results are extremely similar in the case of
Repeats and CpG islands; Here we will report only the conditional values;
p,0.001 in all cases;
(Repeats and CPG variables are rescaled; we report on the ZIP model for miRNA
and the Poisson model for genes; both models include chromosome dummies
and the statistically significant interactions between chromosomes and site
fragility; models also control for the differential exposure associated to differing
site lengths).
doi:10.1371/journal.pone.0011166.t003
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distribution of miRNAs and genes in fragile vs. non-fragile sites
depended on chromosome. Our chromosome-specific results show
that the distribution of miRNAs is actually significantly different
from that of genes. For example, in chromosome 19 we observe
that the incidence of miRNAs in fragile sites is twenty-nine times
higher than in non-fragile regions, versus nine times higher for
genes. Surprisingly we even find that, although on average regions
with fragile sites are denser in miRNAs and genes, when looking at
specific chromosomes sometimes the reverse happens. For
example, in chromosome 14 there is a lower incidence of miRNAs
in fragile regions. Hence, the incidence of miRNAs and of protein
coding genes on fragile versus non-fragile sites depends on
chromosome. This is a novel result that has not been presented
in previous literature and that reveals that the distribution of
miRNAs and genes is far more complex than previously thought.
Moreover, we also find that almost half of miRNAs are located
near or within genes translocated in cancer.
Our data also show a positive correlation between chromosome
fragility and repeats. mir-616 and mir-28 are derived from
transposed elements (LINE, L2 family) [29] and are located within
two translocation breakpoints, respectively DDIT3, that is often
fused to FUS in myxoid liposarcoma [30], and LPP, that is fused
to MLL in a secondary acute leukemia [31]. Moreover several
human microRNAs are transcribed by RNA polymerase III
through promoters and/or terminators derived from the Alu
retrotransposon [32] and all these miRNA genes are located in
chromosome 19 within FRA19A (5-azacytidine type, common).
Chromosome 19 has a high Alu elements density, highly
correlated with GC content [33]. A primate-specific gene cluster
on chromosome 19 encodes the majority of miRNAs that show
high seed complementarity to the most conserved sense Alu sites.
A dual relationship exists between this evolutionary young miRNA
cluster and their Alu targets that may have evolved in the same
time window. One hypothesis for this dual relationship is that
these miRNAs could protect against too high rates of duplicative
transposition, which would destroy the genome [34].
The high correlation that we found between miRNAs and CpG
island is consistent with some recent findings. Several miRNA loci,
including miR-9-1, -193a, -137, -342, -203 and -34b/c, are found
to be hypermethylated in multiple human cancers [35]. Con-
versely, the let-7a-3 locus was found to be hypomethylated in lung
adenocarcinoma and elevated expression of this locus resulted in
enhanced oncogenic gene transcription [16].
The expression of fragile sites could also be affected by the
environment and other factors such as alcohol and smoke. mir-218
(miR-218-1) is down-regulated in smokers [36] and it is encoded
within the intronic region of the known tumor suppressor gene
SLIT2 located at 4p15.31. SLIT2, which is frequently inactivated
in lung and breast tumors [37], is significantly down-regulated in
smokers with expression correlating to that of mir-218 [36]. A
second copy of miR-218 (miR-218-2) occurs within the SLIT3
locus located at 5q35.1, and expression of SLIT3 has also been
shown to be down-regulated in lung cancer [38]. In general,
chromosomal aberrations of chromosome 4 and 5 at multiple sites
are frequent in lung cancer [39,40]. Interestingly, miR-218-1 is
located within FRA4D (aphidicolin type, common) and miR-218-
2 is located within FRA5G (folic acid type, rare). Alteration of mir-
218 levels diminishes the induction of the predicted mir-218 target
MAFG in response to cigarette smoke condensate (CSC). miRNAs
implicated in carcinogenesis are differentially expressed in the
airway epithelium of smokers. This suggests that airway miRNA
expression could potentially serve as an indicator of smoking-
induced disease processes. Down-regulation of miRNAs in
smokers could be related to the development of tobacco-related
cancers [36].
Alcoholics also reveal a significantly higher frequency of fragile
sites and chromosomal aberrations and the most frequent
exchange types are deletions and polymorphic variations [41].
The specific chromosomal regions 1p36 (FRA1A), 1q21 (FRA1F),
2q21 (FRA2F), 2q31 (FRA2G), 5q31 (FRA5C), 7q22 (FRA7F),
7q32 (FRA7H) and 12q13 (FRA12A) are associated with
chromosomal aberrations in alcoholics and many miRNAs, such
as those in the mir-106b-25 cluster, are located within these fragile
sites. Recently, it has been observed that the mir-106b-25 cluster
(which includes miR-106b, miR-93 and miR-25, and is located at
FRA7F) is over-expressed in hepatocellular carcinoma [42], a
malignant tumor which is often related to high alcohol
consumption [43]. In tumors with high expression of this cluster,
a reduced expression of Bim, a miR-25 target and a critical
regulator of apoptosis that plays an essential role in mammalian
development, is observed [42]. This data suggests a possible
correlation between alcohol assumption, chromosomal aberration
of the region 7q22 and the mir-106b-25 cluster expression.
Since the prediction of miRNA targets still remains a challenge
[44], the reported data may help to highlight significant
correlations between the miRNAs and their predicted targets
and to elucidate the role of miRNAs in cancer and other diseases,
due to their genomic locations.
For example, rearrangements of chromosome 5, especially 5p
gain, are often related to cervical cancer [45], and a miRNA
located at 5p13.3, miR-579, is predicted to target the genes
PTGS2 and IRF1, which are involved in cervical cancer.
Moreover this miRNA is co-localized with RNASEN (Drosha), a
gene which plays a key role in miRNA biogenesis and whose over-
expression is observed in cervical cancer [45]. These data are
consistent with the inactivation of IRF1 in various cancers.
Chromosome 19 has the highest gene density of all human
chromosomes, more than double the genome-wide average, and
the greatest incidence of miRNAs in fragile regions. The high
number of miRNAs could be due to the high number of repeats
which also may contribute to chromosome fragility (as we
previously discussed). A telomeric association of the long arms of
chromosome 19 (19q13.4) has been associated to Premature
Ovarian Failure (POF) [46]. Our analysis shows a possible
involvement of several members of the miR-515 family (such as
miR-515-5p, miR-519 and miR-520a-3p/b/c-3p/d-3p/e/g/h),
located at 19q13.4, in POF, since they are predicted to target
FMR1 and FOXL2, two genes which are associated to POF
[47,48].
In conclusion, the presented data underline the importance of
having detailed information about the miRNAs co-localization
with genome fragile sites and unstable regions, in order to
formulate hypoteses of targeting and involvement of miRNAs in
diseases and biological processes. However, our results also reveal
that fragile regions appear to be also denser in protein coding
genes. It is when chromosome effects and interactions are allowed
that significant differences in distribution between miRNAs and
genes are observed. This demonstrates that the mechanisms
regulating these unstable regions are more complex than what an
analysis pooling all sites together could reveal. A local analysis of
the incidence of miRNAs and genes is required.
All the collected data are available as supplementary material,
and are being integrated into miRo `, a web-based environment
which provides users with powerful query tools for finding non-
trivial associations among heterogeneous data such as miRNAs,
processes, functions, diseases and expression profiles [49]. Such
integration will make easier the study of the relationships between
miRNAs in Fragile Sites
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data sets and the extraction of non-trivial associations by the use of
data mining facilities.
As a final note we emphasize that most fragile sites boundaries
have not been characterized yet and are not known. As a result, in
our study and following previous research [4,50,51,52,53], we
mapped fragile sites to chromosomal bands and divided the 23
chromosomes into fragile and non-fragile regions (see Materials
and Methods for further details). Therefore, some of the miRNAs
mapping close to a fragile site may be in reality megabase pairs
away. However, it is not known how close to a fragile site a
miRNA must be in order for it to be affected. This limitation of
our study demonstrates the need for further work in this area and
for a more specific mapping of fragile sites. Despite these
limitations, we feel that the approach we took to build the dataset
is the best that can be applied at the moment.
Materials and Methods
The datasets
The set of the human miRNA genes is based on the release 13.0
(March 2009) of miRBase [54] and contains 715 miRNAs.
The fragile sites set consists of 118 genomic regions retrieved
from NCBI Gene repository based on the Build 36.3 of the human
genome. Most fragile sites boundaries have not been characterized
yet. Data are available for only few of them, but this data is often
susceptible of changes. For example, the fragile region FRA3B had
been characterized as a large region of genomic instability
covering 500 kb [55,56,57,58]. However, Becker et al. [59],
report that fragility at FRA3B actually extends over a 4 Mb region
containing five genes.
For this reason, consistent with previous work [4,50,51,52,53]
and with the NCBI MapViewer data, we mapped fragile sites to
specific chromosomal bands. We then divided the 23 chromo-
somes into regions by looking at their sequential positioning (e.g.,
two sequential bands associated with fragile sites are grouped
together to form a fragile region, and so on). We then determined
the size of each region and classified the regions as having or not a
fragile site by creating a fragile dummy variable (if a region has at
least one fragile site the dummy will take the value 1, and if the
region does not contain any fragile site the dummy takes the value
0). This way we created the 205 fragile and non-fragile regions
used in our analysis.
The translocation breakpoints related to cancer come from
TICdb [60] and their location is obtained by Ensembl 54. Fragile
sites, translocation breakpoints and miRNAs are also annotated
with information on the diseases in which they are known or
predicted to be involved. These data come from miR2Disease
(experimentally supported miRNA-disease associations) [61],
miRo ` (predicted miRNA-disease associations) [49], OMIM,
Mitelman Database of Chromosome Aberrations in Cancer [62]
and the Chromosomal Variation in Man website (a database
which contains a review of the literature on all common and rare
chromosomal alterations and abnormalities) [63]. MicroRNA
precursors structurally derived from transposable elements are
obtained from the microTranspoGene database [29]. Finally, the
CpG islands and the repetitive sequences are retrieved from the
NCBI database.
Statistical Analysis
Due to the discrete nature of the data, we used Poisson models
to test whether miRNAs and protein coding genes appear more
frequently in fragile sites. In these separate analyses, ‘‘events’’ were
defined as the number of miRNAs or as the number of protein
coding genes in each genomic region (depending on whether we
are studying miRNA or gene incidence). We control for the size of
genomic regions by directly accounting for the differential
exposure due to region length (the length of each region is known
and regions can vary significantly in size). We have also accounted
for chromosome differences and allowed each chromosome to
contain differing densities of miRNA and genes, irrespective of site
fragility.
We tested the use of chromosome independent and non-
independent random effects, RE, and of chromosome specific
fixed effects (FE). After comparing model statistics (Bayesian
Information Criterion, BIC, and Akaike Information Criterion,
AIC), and after performing the Hausman test (5% significance), we
conclude that chromosome dummies provided a better represen-
tation of the data for both miRNA and genes. We note however
that the use of random effects does not alter significantly the results
both in terms of parameter values and in terms of inference (when
one effect is significant in one formulation it is also significant
under the alternative formulation, and vice-versa; see Tables S6,
S7, and S8 for an example comparing results from RE and FE
version of the same model). Differences in inference could be
present as RE models can at times be more efficient and have
lower standard errors. We did not observe any significant
difference also in inference (Tables S6, S7, and S8).
We note also that FE models are always consistent and that
these are statistically a very reasonable formulation in our context
because of the reduced number of cross-sectional units (23
chromosomes). As a result, the FE formulation does not require
the use of an excessive number of parameters that could
‘‘consume’’ degrees of freedom during estimation and inference.
At the same time it avoids any distributional assumptions on
chromosome effects and it does not require that the random effects
and model error terms be orthogonal. Finally, with a FE
formulation we were able to flexibly include or exclude specific
effects depending on their statistical significance, a task that is
extremely difficult with RE (with RE once the chromosome effect
is included all chromosomes have a differing parameter, even
when not statistically significantly).
Hence, the results reported are for the models including
chromosome dummies.
We further tested whether a Zero-Inflated Poisson (ZIP) model
better fits the miRNA data (more than 30% of the miRNA
observations are zero; protein coding genes do not present this
characteristic and do not pose a problem for the use of standard
Poisson models). Comparing the fit (BIC and AIC) of a ZIP model
against that of traditional Poisson we concluded that the ZIP
model is preferred (the ZIP model considers a Logit formulation
for the zero-inflation component, with a constant and length as
inflation variables; it separately models the zero case in the data
and is especially useful in obtaining better parameter estimates
when the data presents an excessive number of zeros, a feature
standard Poisson models cannot easily accommodate).
Because of these results, the parameters reported for the
miRNA variable are from the estimation of the ZIP model (for
genes, the standard Poisson performed the best, as expected). We
also analyzed for overdispersion of miRNA and genes data and
concluded it was not a significant problem making Poisson (or ZIP)
models adequate for modeling miRNA and genes.
In a separate analysis, to test whether fragile sites are associated
with a higher incidence of repeats and CpG islands we estimated a
Logit model of site fragility using repeats and CpG islands as
predictors. The ‘‘event’’ to be modeled in this analysis is whether a
genomic region is classified as fragile or not (a yes/no type of
variable for which the Logit is the adequate model; we no longer
miRNAs in Fragile Sites
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(chromosome dummies) to account for heterogeneity in incidence
of fragile sites across chromosomes, and we found that
chromosome dummies provided the best fit (however no
significant difference in the main coefficients and inference
between the two alternatives was found; in addition, the
considerations regarding the RE and FE formulations we
presented before also applied to this case).
Conversely, we have modeled the number of repeats and the
number of CpG islands as a function of site fragility using standard
Poisson models (no excessive number of zeros or overdispersion
observed; indeed a ZIP model did not fit the data better than the
standard Poisson model by comparing AIC and BIC fit measures).
The analyses of site fragility and of CpG and Repeats are
complementary as there is not clear causality relationship between
these variables (i.e., it is unclear whether site fragility is caused by
the presence of higher number of repeats and CpG islands or
whether the reverse is true).
All computations were completed using STATA v10.0. We report
the incidence rate ratio (IRR) and the two-sided 95% confidence
intervals of the IRR. An IRR significantly .1 indicates an increase in
the number of the dependent variable (either miRNA or genes,
d e p e n d i n go nt h ea n a l y s i s )w i t h i nar e g i o no fac e r t a i nt y p e( e . g . ,i n
the miRNA model a ‘‘Fragile IRR’’ .1 means that fragile regions are
more likely to contain miRNA than non-fragile sites).
We note that the statistical inference performed considered
always a 5% significance level. In addition, standard errors were
computed using the Observed Information Matrix method for
most parameters. When estimating the RE formulation standard
errors of the random effects (either for the intercept and for the
‘‘slope’’ parameters, as is the case of the parameter associated with
the fragile dummy) the random effects and corresponding standard
errors were estimated using the Best Linear Unbiased Predictor
(BLUP) and the ‘predict’ function in STATA associated with the
‘xtmepoisson’o r‘ xtmelogit’ fucntions.
When performing statistical testing on parameters, we used a t-
test with (N–k) degrees of freedom (where N is the number of
observations and k the number of parameters of the estimated
model). When testing differences of parameters we also used a t-
test and estimated the standard error of the difference using the
delta method (if coming from two different samples assumed that
samples were independent).
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